We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




High HbA1c Levels Linked to Pregnancy Risks

By LabMedica International staff writers
Posted on 08 May 2019
For pregnant women with diabetes mellitus some particular challenges exist for both mother and child. More...
If the woman has diabetes as an intercurrent disease in pregnancy, it can cause early labor, birth defects, and larger than average infants.

High blood sugar levels are harmful to the mother and her fetus. Experts advise diabetics to maintain blood sugar level close to normal range for two to three months before planning for pregnancy. Managing blood sugar close to normal before and during pregnancy helps to protect the health of mother and the baby.

Maternal type 1 diabetes (T1D) has been linked to preterm birth and other adverse pregnancy outcomes. Scientists at the Karolinska Institute (Solna, Sweden) and their associates examined how these risks vary with glycated hemoglobin (or HbA1c) levels. They examined preterm birth risk according to periconceptional HbA1c levels in women with T1D. In a population-based cohort study carried out from 2003 to 2014 and they followed 2,474 singletons born to women with T1D and 1,165,216 reference infants born to women without diabetes. Measurement for the study included risk for preterm birth (<37 gestational weeks), secondary outcomes were neonatal death, large for gestational age, macrosomia, infant birth injury, hypoglycemia, respiratory distress, 5-minute Apgar score less than 7, and stillbirth.

The investigators reported that preterm birth occurred in 552 (22.3%) of 2,474 infants born to mothers with T1D versus 54,287 (4.7%) in the infants born to mothers without diabetes. The incidence of preterm birth was 13.2% in women with a periconceptional HbA1c level below 6.5% (adjusted risk ratio [aRR] versus women without T1D, 2.83), 20.6% in those with a level from 6.5% to less than 7.8% (aRR, 4.22), 28.3% in those with a level from 7.8% to less than 9.1% (aRR, 5.56) and 37.5% in those with a level of 9.1% or higher (aRR, 6.91). The corresponding aRRs for 320 medically indicated preterm birth were 5.26, 7.42, 11.75, and 17.51, respectively. The corresponding aRRs for 223 spontaneous preterm birth were 1.81, 2.86, 2.88, and 2.80, respectively.

Increasing HbA1c levels were associated with the study's secondary outcomes: large for gestational age, hypoglycemia, respiratory distress, low Apgar score, neonatal death, and stillbirth. Jonas F. Ludvigsson, MD, PhD, a professor of pediatrics and lead author of the study, said, “This is the first study large enough to demonstrate a clear relationship between different hemoglobin A1C (Hb A1C) levels and preterm birth. Our study has been conducted nationally and thus provides a result that can be applied to the average woman with type 1 diabetes.” The study was published on April 23, 2019, in the journal Annals of Internal Medicine.

Related Links:
Karolinska Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researchers developed a blood test that accurately distinguishes early-stage breast cancer from healthy controls and may outperform tissue biopsy in predicting recurrence risk (Image Credit: Adobe Stock)

Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk

Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.